Integral Health Asset Management LLC Purchases 50,000 Shares of Glaukos Corporation $GKOS

Integral Health Asset Management LLC boosted its position in Glaukos Corporation (NYSE:GKOS) by 100.0% during the 3rd quarter, Holdings Channel reports. The fund owned 100,000 shares of the medical instruments supplier’s stock after buying an additional 50,000 shares during the period. Integral Health Asset Management LLC’s holdings in Glaukos were worth $8,155,000 as of its most recent SEC filing.

A number of other hedge funds have also recently added to or reduced their stakes in GKOS. UMB Bank n.a. raised its position in shares of Glaukos by 102.6% during the third quarter. UMB Bank n.a. now owns 312 shares of the medical instruments supplier’s stock worth $25,000 after purchasing an additional 158 shares during the period. REAP Financial Group LLC acquired a new stake in Glaukos in the 3rd quarter valued at $40,000. Smartleaf Asset Management LLC increased its stake in Glaukos by 16.2% during the 2nd quarter. Smartleaf Asset Management LLC now owns 973 shares of the medical instruments supplier’s stock valued at $99,000 after purchasing an additional 136 shares in the last quarter. SBI Securities Co. Ltd. increased its stake in Glaukos by 42.9% during the 3rd quarter. SBI Securities Co. Ltd. now owns 1,205 shares of the medical instruments supplier’s stock valued at $98,000 after purchasing an additional 362 shares in the last quarter. Finally, State of Wyoming raised its holdings in Glaukos by 13.1% during the third quarter. State of Wyoming now owns 1,723 shares of the medical instruments supplier’s stock worth $141,000 after buying an additional 199 shares during the last quarter. Institutional investors and hedge funds own 99.04% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts have weighed in on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Glaukos in a research note on Thursday, January 22nd. William Blair upgraded shares of Glaukos to a “strong-buy” rating in a report on Friday, January 30th. Wall Street Zen cut shares of Glaukos from a “buy” rating to a “hold” rating in a research report on Saturday, February 21st. Wells Fargo & Company lifted their price target on Glaukos from $122.00 to $135.00 and gave the company an “overweight” rating in a research note on Wednesday, February 18th. Finally, UBS Group boosted their price objective on Glaukos from $140.00 to $145.00 and gave the stock a “buy” rating in a report on Tuesday, December 23rd. One investment analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating, one has assigned a Hold rating and two have issued a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $133.69.

Insider Activity

In other news, Director Aimee S. Weisner sold 15,000 shares of the business’s stock in a transaction that occurred on Thursday, February 19th. The stock was sold at an average price of $117.38, for a total value of $1,760,700.00. Following the transaction, the director owned 18,806 shares in the company, valued at $2,207,448.28. The trade was a 44.37% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Thomas William Burns sold 186,945 shares of the business’s stock in a transaction that occurred on Friday, January 16th. The stock was sold at an average price of $115.00, for a total value of $21,498,675.00. Following the completion of the transaction, the chief executive officer owned 153,775 shares in the company, valued at $17,684,125. The trade was a 54.87% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders sold 320,000 shares of company stock valued at $37,202,909. 5.80% of the stock is currently owned by company insiders.

Glaukos Price Performance

GKOS opened at $96.89 on Friday. Glaukos Corporation has a 1 year low of $73.16 and a 1 year high of $130.23. The company has a debt-to-equity ratio of 0.10, a current ratio of 4.69 and a quick ratio of 4.06. The company has a market capitalization of $5.63 billion, a price-to-earnings ratio of -29.72 and a beta of 0.70. The firm’s fifty day moving average price is $114.63 and its two-hundred day moving average price is $101.20.

Glaukos (NYSE:GKOS) last announced its earnings results on Tuesday, February 17th. The medical instruments supplier reported ($0.28) EPS for the quarter, missing the consensus estimate of ($0.22) by ($0.06). Glaukos had a negative net margin of 36.99% and a negative return on equity of 7.00%. The firm had revenue of $143.12 million during the quarter, compared to analysts’ expectations of $132.16 million. During the same quarter in the prior year, the company earned ($0.40) EPS. The business’s revenue for the quarter was up 35.6% on a year-over-year basis. As a group, analysts anticipate that Glaukos Corporation will post -1.08 earnings per share for the current fiscal year.

About Glaukos

Glaukos Corporation is a medical technology company specializing in the development, manufacturing and commercialization of innovative therapies for patients with glaucoma and other chronic eye diseases. The company’s core offerings focus on micro-invasive glaucoma surgery (MIGS), designed to reduce intraocular pressure and manage glaucoma more safely and effectively than traditional surgical approaches. Glaukos’s flagship products include the iStent, iStent inject and iStent infinite trabecular micro-bypass stents, which are implanted during cataract surgery to improve aqueous outflow and help control eye pressure.

Beyond its MIGS portfolio, Glaukos has expanded into sustained drug-delivery solutions.